“…One randomized, placebocontrolled trial of 12 weeks treatment with genistein in men with early prostate cancer found no significant difference in PSA levels between the treatment and placebo groups (Kumar et al, 2004), although the authors suggested that surrogate measures were being affected by treatment. Other trials support the idea that isoflavones, even given over relatively short periods of time, can possibly slow the rate of rise of PSA, though no statistically significant conclusions can be drawn (Dalais et al, 2004;Hussain et al, 2003;Maskarinec et al, 2006;Pendleton et al, 2008 (Davis et al, 2000;Takahashi et al, 2006;Tepper et al, 2007) b. c. d. (Nakamura et al, 2002;Tsui et al, 2008 (Davis et al, 1998) b. (Palozza et al, 2010) c. (Benitez et al, 2007;Kuwajerwala et al, 2002) d. (Davis et al, 1998;Lian et al, 1998) c. (Benitez et al, 2007;Kuwajerwala et al, 2002;Mitchell et al, 1999) d. (Bhatia & Agarwal, 2001;Kazi et al, 2003;Rice et al, 2007) c. (Benitez et al, 2007;Kuwajerwala et al, 2002) d. Protein tyrosine kinase a. Inhibition of EGF tyrosine kinase activation by genistein c. Resveratrol inhibits tyrosine kinase d. Curcumin inhibits EGF-R signaling a.…”